[go: up one dir, main page]

MX2022010011A - Inhibidores de prmt5 novedosos. - Google Patents

Inhibidores de prmt5 novedosos.

Info

Publication number
MX2022010011A
MX2022010011A MX2022010011A MX2022010011A MX2022010011A MX 2022010011 A MX2022010011 A MX 2022010011A MX 2022010011 A MX2022010011 A MX 2022010011A MX 2022010011 A MX2022010011 A MX 2022010011A MX 2022010011 A MX2022010011 A MX 2022010011A
Authority
MX
Mexico
Prior art keywords
compounds
prmt5 inhibitors
formula
novel
novel prmt5
Prior art date
Application number
MX2022010011A
Other languages
English (en)
Inventor
Brian Alan Lanman
Matthew R Kaller
Qingyian Liu
Vu Van Ma
Albert Amegadzie
Alexander J Pickrell
Michael J Frohn
Patricia Lopez
Nuria A Tamayo
John R Butler
Ana Elena Minatti
Shon Booker
Todd J Kohn
Jennifer Rebecca Allen
Matthew Paul Bourbeau
Kexue Li
Francesco Manoni
Jose Medina
Cadahia Jorge Peiro
Liping Pettus
Ian Sarvary
Mikkel Vestergaard
Diane Jennifer Beylkin
Sanne Ormholt Schroder Glad
Birgitte Weinreich Husemoen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2022010011A publication Critical patent/MX2022010011A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen en el presente documento compuestos de fórmula I y sales farmacéuticamente aceptables de los mismos, estereoisómeros, tautómeros así como composiciones farmacéuticas de los mismos. Los compuestos de la presente invención son útiles para inhibir la actividad de PRMT5 y pueden tener uso en el tratamiento de trastornos proliferativos, metabólicos y sanguíneos. Los compuestos de fórmula I tienen la siguiente estructura: (I) (Ver Fórmula I).
MX2022010011A 2020-02-12 2021-02-11 Inhibidores de prmt5 novedosos. MX2022010011A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062975258P 2020-02-12 2020-02-12
PCT/US2021/017682 WO2021163344A1 (en) 2020-02-12 2021-02-11 Novel prmt5 inhibitors

Publications (1)

Publication Number Publication Date
MX2022010011A true MX2022010011A (es) 2022-10-18

Family

ID=75539888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010011A MX2022010011A (es) 2020-02-12 2021-02-11 Inhibidores de prmt5 novedosos.

Country Status (7)

Country Link
US (1) US20230159510A1 (es)
EP (1) EP4103558A1 (es)
JP (1) JP7787819B2 (es)
AU (1) AU2021219730A1 (es)
CA (1) CA3170321A1 (es)
MX (1) MX2022010011A (es)
WO (1) WO2021163344A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
WO2022026892A1 (en) 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers
JP7487421B2 (ja) * 2020-12-16 2024-05-20 アムジエン・インコーポレーテツド Ｐｒｍｔ５阻害剤
TW202319046A (zh) * 2021-08-30 2023-05-16 美商安進公司 用於合成㖠啶衍生物及其中間體之方法
WO2023072240A1 (en) 2021-10-28 2023-05-04 Insilico Medicine Ip Limited Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
IL315996A (en) * 2022-04-08 2024-11-01 Amgen Inc Cancer treatments using PRMT5 inhibitors in collaboration with MTA
US20230365521A1 (en) * 2022-04-22 2023-11-16 The Board Of Trustees Of The University Of Illinois Compounds for increasing the nicotinamide adenine dinucleotide in a subject and methods of use thereof
WO2023207556A1 (zh) * 2022-04-27 2023-11-02 苏州浦合医药科技有限公司 Prmt5-mta抑制剂
WO2023246873A1 (zh) * 2022-06-23 2023-12-28 南京明德新药研发有限公司 氨基取代的杂芳基衍生物及其应用
EP4549442A1 (en) * 2022-07-01 2025-05-07 Cytosinlab Therapeutics Co., Ltd. Prmt5 inhibitors and use thereof
WO2024008113A1 (zh) * 2022-07-07 2024-01-11 深圳微芯生物科技股份有限公司 一种甲酰胺取代的杂三环类衍生物、其制备方法及其应用
WO2024021957A1 (zh) * 2022-07-26 2024-02-01 上海和誉生物医药科技有限公司 一种prmt5抑制剂及其制备方法和药学上的应用
CN119730853A (zh) 2022-08-15 2025-03-28 阿斯利康(瑞典)有限公司 用于治疗癌症的mta协同prmt5抑制剂
CN119677755A (zh) * 2022-08-18 2025-03-21 南京明德新药研发有限公司 含酰胺的杂环衍生物及其应用
CN117658980A (zh) * 2022-09-08 2024-03-08 郑州同源康医药有限公司 双环类prmt5抑制剂
WO2024074611A1 (en) * 2022-10-05 2024-04-11 Ryvu Therapeutics S.A. Prmt5 inhibitors
IL321326A (en) * 2022-12-21 2025-08-01 Amgen Inc Cancer therapies using PRMT5 inhibitors collaborate with MTA
WO2024131901A1 (zh) * 2022-12-23 2024-06-27 深圳微芯生物科技股份有限公司 一类含炔基取代的杂环酰胺衍生物、其制备方法及其应用
WO2024140923A1 (zh) * 2022-12-30 2024-07-04 苏州浦合医药科技有限公司 Prmt5-mta抑制剂
WO2024153128A1 (en) 2023-01-18 2024-07-25 Shanghai Antengene Corporation Limited Prmt5 inhibiting compounds and uses thereof
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy
US20240368177A1 (en) * 2023-03-30 2024-11-07 Beigene Switzerland Gmbh 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5
KR20250175331A (ko) 2023-04-21 2025-12-16 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
WO2024222660A1 (zh) * 2023-04-23 2024-10-31 勤浩医药（苏州）有限公司 酰胺类化合物、包含其的药物组合物及其用途
AU2024264196A1 (en) * 2023-04-28 2025-11-27 Pharmaengine, Inc. Mta-cooperative prmt5 inhibitor
WO2024234821A1 (zh) * 2023-05-17 2024-11-21 四川科伦博泰生物医药股份有限公司 三并环酰胺化合物、包含其的药物组合物及其制备方法和用途
CN121127465A (zh) * 2023-07-14 2025-12-12 江苏亚虹医药科技股份有限公司 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
WO2025026381A1 (zh) * 2023-08-02 2025-02-06 成都微芯药业有限公司 杂环炔基取代的酰胺衍生物、其制备方法及其应用
WO2025039979A1 (zh) * 2023-08-18 2025-02-27 江苏亚虹医药科技股份有限公司 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
WO2025098450A1 (zh) * 2023-11-08 2025-05-15 北京泰德制药股份有限公司 Prmt5抑制剂及其制备方法
TW202540126A (zh) * 2023-12-01 2025-10-16 大陸商上海翰森生物醫藥科技有限公司 三並環類衍生物抑制劑、其製備方法和應用
WO2025119326A1 (zh) * 2023-12-07 2025-06-12 上海湃隆生物科技有限公司 新型prmt5抑制剂及其应用
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025218671A1 (en) * 2024-04-16 2025-10-23 Shanghai Apeiron Therapeutics Company Limited Novel prmt5 proteolysis targeting chimeric molecules and associated methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100937738B1 (ko) * 2007-12-14 2010-01-21 한국과학기술연구원 퀴놀린 카복실산 아마이드 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 항균 조성물
WO2016022605A1 (en) * 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof

Also Published As

Publication number Publication date
EP4103558A1 (en) 2022-12-21
US20230159510A1 (en) 2023-05-25
WO2021163344A1 (en) 2021-08-19
CA3170321A1 (en) 2021-08-19
AU2021219730A1 (en) 2022-08-25
JP2023513580A (ja) 2023-03-31
JP7787819B2 (ja) 2025-12-17

Similar Documents

Publication Publication Date Title
MX2022010011A (es) Inhibidores de prmt5 novedosos.
CR20230310A (es) Inhibidores de prmt5
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
SA523440916B1 (ar) Prmt5 مشتقات كربوكساميد ثلاثية الحلقة كمثبطات
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
MX2024011056A (es) Compuesto heterociclico para inducir la degradacion de la proteina kras mutante g12d.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2022008881A (es) Compuesto heterociclico de pirimidin-4(3h)-ona, metodo de preparacion del mismo y su uso farmaceutico.
GEP20257750B (en) 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
WO2021147236A9 (zh) 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用
GEAP202515818A (en) Amino quinazoline derivatives as p2x3 inhibitors
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
EA201991916A1 (ru) 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
MX2022004878A (es) Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos.
PH12022552727A1 (en) COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2a AND THEIR METHODS OF USE
MX2024002409A (es) Terapias contra el cancer.
MX2024011705A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica
MX2025001865A (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
GEP20257771B (en) Compounds and compositions as sppl2a inhibitors
MX2025006234A (es) Derivados de fenilpiperidina como inhibidores de la glutaminil-peptido ciclotransferasa y proteina similar a glutaminil-peptido ciclotransferasa
MX2025000582A (es) Inhibidores de tirosina cinasa 2 y usos de estos
MX2025006420A (es) Inhibidores de adar1 y métodos de uso de estos
PH12021550093A1 (en) Compounds for use in the treatment of fascioliasis